ITF Therapeutics Shares Update on DUVYZAT™ Following FDA Approval
Following the FDA’s approval of DUVYZAT™ (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the company responsible for producing and marketing DUVYZAT™ in the United States, today shared an update on the drug and related…Learn More
